Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Equities research analysts at Leerink Swann issued their Q1 2018 earnings per share estimates for Amicus Therapeutics in a research report issued on Thursday. Leerink Swann analyst J. Schwartz anticipates that the biopharmaceutical company will earn ($0.32) per share for the quarter. Leerink Swann currently has a “Outperform” rating and a $24.00 target price on the stock. Leerink Swann also issued estimates for Amicus Therapeutics’ Q2 2018 earnings at ($0.32) EPS, Q3 2018 earnings at ($0.32) EPS, Q4 2018 earnings at ($0.32) EPS, FY2018 earnings at ($1.29) EPS, FY2019 earnings at ($0.93) EPS and FY2020 earnings at ($0.84) EPS.
FOLD has been the topic of a number of other reports. Zacks Investment Research cut Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, December 19th. Robert W. Baird set a $20.00 target price on Amicus Therapeutics and gave the stock a “buy” rating in a report on Wednesday, February 7th. BidaskClub upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, January 15th. Cowen reiterated a “buy” rating and issued a $22.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 10th. Finally, ValuEngine upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $19.06.
In other Amicus Therapeutics news, CEO John F. Crowley sold 47,213 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $13.61, for a total transaction of $642,568.93. Following the transaction, the chief executive officer now directly owns 375,214 shares in the company, valued at approximately $5,106,662.54. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO John F. Crowley sold 12,206 shares of the firm’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $13.52, for a total value of $165,025.12. Following the transaction, the chief executive officer now owns 340,207 shares in the company, valued at $4,599,598.64. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 250,390 shares of company stock worth $3,620,581. Company insiders own 3.40% of the company’s stock.
A number of large investors have recently modified their holdings of FOLD. Strs Ohio bought a new position in Amicus Therapeutics during the 3rd quarter valued at $102,000. Tudor Investment Corp ET AL bought a new position in Amicus Therapeutics during the 2nd quarter valued at $124,000. Birchview Capital LP bought a new position in Amicus Therapeutics during the 3rd quarter valued at $151,000. Sage Capital Advisors llc bought a new position in Amicus Therapeutics during the 3rd quarter valued at $154,000. Finally, Engineers Gate Manager LP bought a new position in Amicus Therapeutics during the 3rd quarter valued at $155,000.
ILLEGAL ACTIVITY NOTICE: “Research Analysts Issue Forecasts for Amicus Therapeutics, Inc.’s Q1 2018 Earnings (FOLD)” was published by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/02/12/research-analysts-issue-forecasts-for-amicus-therapeutics-inc-s-q1-2018-earnings-fold.html.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.